Culprit vs Multivalve Transcatheter Intervention
|
|
- Willis Owens
- 6 years ago
- Views:
Transcription
1 Culprit vs Multivalve Transcatheter Intervention Howard C. Herrmann, MD, FACC, MSCAI John Bryfogle Professor of Cardiovascular Medicine and Surgery Health System Director for Interventional Cardiology Director, Cardiac Cath Labs, Hospital of the Univ of PA Perelman School of Medicine University of Pennsylvania Philadelphia
2 Typical Patients with Increased Surgical Risk Aortic Stenosis and Mitral Regurgitation Mitral and Tricuspid Regurgitation Aortic Stenosis and CAD HOCM and Mitral Regurgitation Aortic and Mitral (MAC) Stenosis
3 Philosophy of Culprit vs Multivalve Intervention Cardiac Surgeons ---- Interventional Cardiologists Risk of additional surgery Comparative risk of treating only one lesion versus surgery Risk of not recovering from CPB/surgery if leave residual disease Medical management of 1 vs multiple lesions
4 Case 1 75 yo woman with h/o rheumatic heart disease AR/MR underwent surgery 2009: bio AVR (#25 Magna pericardial) bio MVR (#29 CE pericardial) Jan, 2017, developed DOE (class II-III), AF, TIAs PH: Type 2 DM Hypothyroidism OSA HTN Mild short term memory loss Frailty (2/4) DCCV/TEE: prosthetic MS (mean grad 9), moderately severe AS (mean grad 28), LV dysfunction (EF 35%) Unable to maintain SR -> warfarin OAC, continued symptoms Referred to Penn CV Surgery
5 STS Risk Calculation Isolated AV Replacement = 6.9% Isolated MV Replacement = 9.5% What therapy would you offer this patient? 1. Double Re-do Valve Replacement at >10% risk 2. Re-do MVR with plan for staged TAVR in the future 3. TMVR VIV (transseptal) with staged TAVR 4. TMVR VIV and TAVR transapically (one procedure)
6 Case 1 Echo
7 Case 1 Now that you have seen the most current echo, what would you recommend? 1. Double Re-do Valve Replacement at >10% risk 2. Re-do MVR with plan for staged TAVR in the future 3. TMVR VIV (transseptal) with staged TAVR 4. TAVR with staged TMVR VIV 5. TMVR VIV and TAVR transapically (one procedure)
8 Case 1 Procedure 1 #26 Corevalve Evolut R VIV TF, conscious sedation Discharged day #2 TTE: Mean AV grad 21 mmhg DVI 0.40 Trace to mild PVL Mean MV grad 12 mmhg
9 Case 1 Procedure 2: Baseline imaging
10 Case 1 Procedure 2: Procedure
11 Case 1 Procedure 2: Results
12 Case 2 88 yo man referred in 2015 after presenting with CHF, new AF Class II symptoms on meds (can walk up 1 flight, but symptoms pulling his trash can). No orthopnea, PND. PH: Zenker s diverticulum PUD Hypothyroid Meds: Diltiazem, furosemide, Synthroid, metop, warfarin TTE ordered
13 Case 2 Echo EF 60% Mild-Mod AS (mean grad 12 mmhg, AVA 1.0 cm2, SVI 27 ml/mm2, mild AR) Severe MR (partial P2 flail with multisegment prolapse, EROA 0.43 cm2, MR vol 72 ml, PASP 40 mmhg, VC 0.45 cm
14 Case 2 TEE EF 60% Mod AS/mild AR mean grad 12 mmhg AVA 1.0 cm2 SVI 27 ml/mm2 Severe MR (partial P2 flail with multisegment prolapse): EROA 0.43 cm2 MR vol 72 ml VC 0.45 cm PASP 40 mmhg
15 Case 2 STS Risk: Isolated AVR = 4% Isolated MVR = 7% Isolated MVr = 5% What would you recommend to this 88 yo with severe MR, moderately severe LF AS? 1. AVR and MV repair 2. AVR with MV replacement 3. MV surgery alone and plan TAVR when AS is severe 4. MitraClip with staged TAVR 5. Medical management with plan for future double valve
16 Case 2 Procedure MitraClip 1
17 Case 2 Procedure MitraClip 2
18 Case 2 Follow up Did well for close to 2 years when he developed a recurrent episode of AF and echo demonstrated progression of his AS TAVR work up initiated Echo: Peak/mean aortic grads 86/48 mmhg, AVA 0.8 cm2 Mild-mod MR EF 65% Cath: Significant proximal LAD/diag disease
19 Case 2 Cath
20 Case 2 What would you recommend to this 90 yo s/p MitraClip with mildmod residual MR, severe AS and proximal LAD disease? 1. AVR and CABG (STS Risk 5%, frailty = 1/4) 2. TAVR only 3. PCI and TAVR
21 Case 2 Procedures PCI from right radial artery Synergy 3.0 DES to LAD with angiosculpt of diag TF TAVR under MAC 4 wks later Sapien 3 #26 Minor stroke (double vision) Discharged POD #2 Echo Mean grad 8 mmhg Mild PVL Mild-Mod MR EF 70%
22 Case 2: 1 month TTE LV EF 60% Peak/mean Aortic gradients = 10 and 6 mmhg Mild PVL Mild MR, mean grad 1.3 mmhg
Blank DISCLOSURES 1/17/2017 COMPLEX VALVE CASES CHALLENGES IN EVALUATING AND MANAGING MULTIVALVULAR HEART DISEASE ECHO HAWAII 1/23/17 NONE
Blank COMPLEX VALVE CASES ECHO HAWAII 1/23/17 1 David A. Orsinelli, MD, FACC, FASE Professor, Internal Medicine Director, Structural Heart Imaging The Ohio State University Division of Cardiovascular Medicine
More informationManagement of HOCM: Non-Surgical Options
Management of HOCM: Non-Surgical Options Howard C. Herrmann, MD, FACC, MSCAI John Bryfogle Professor of Cardiovascular Medicine and Surgery Health System Director for Interventional Cardiology Director,
More information2/15/2018 DISCLOSURES OBJECTIVES. Consultant for BioSense Webster, a J&J Co. Aortic stenosis background. Short history of TAVR
TRANSCATHETER AORTIC VALVE REPLACEMENT IN 2018: IS IT NOW THE STANDARD OF CARE? 22 ND ANNUAL COASTAL CARDIAC & VASCULAR CONFERENCE FEBRUARY 17, 2018 R. David Anderson, MD, MS, FACC, FSCAI Professor of
More informationDISCLOSURE. Mitral ViV: why? Mitral Valve- in- Valve: Procedural Image Guidance with TEE, a Must Have or Nice to Have? UW Medicine NONE.
Mitral Valve- in- Valve: Procedural Image Guidance with TEE, a Must Have or Nice to Have? G. Burkhard Mackensen, MD, PhD, FASE Professor & Chief, Division of Cardiothoracic Anesthesia, Department of Anesthesiology
More informationCardiac Valve/Structural Therapies
Property of Dr. Chad Rammohan Cardiac Valve/Structural Therapies Chad Rammohan, MD FACC Medical Director, El Camino Hospital Cardiac Catheterization Lab Director, Interventional and Structural Cardiology,
More informationTAVR-Update Andrzej Boguszewski MD, FACC, FSCAI Vice Chairman, Cardiology Mid-Michigan Health Associate Professor Michigan State University, Central
TAVR-Update Andrzej Boguszewski MD, FACC, FSCAI Vice Chairman, Cardiology Mid-Michigan Health Associate Professor Michigan State University, Central Michigan University 1 Disclosure Chiesi Pharma- Consultant
More informationHow Do I Evaluate a Patient Being Considered for TAVR? Sunday, February 14, :00 11:25 PM 25 min
2016 ASE State of the Art Echocardiography Course Tucson, AZ How Do I Evaluate a Patient Being Considered for TAVR? Sunday, February 14, 2016 11:00 11:25 PM 25 min 1 M U H A M E D S A R I Ć, M D, P H D
More informationTEE guided TAVR using BASILICA technique in patient with stenotic Freestyle aortic bioprosthesis
TEE guided TAVR using BASILICA technique in patient with stenotic Freestyle aortic bioprosthesis Zuyue Wang MD Associate professor, Georgetown University School of Medicine MedStar Heart and Vascular Institute
More informationHOW IMPORTANT ARE THESE ECHO MEASUREMENTS ANYWAY?
HOW IMPORTANT ARE THESE ECHO MEASUREMENTS ANYWAY? John D. Carroll, MD Professor, Director of Interventional Cardiology and Co-Medical Director of the Cardiac and Vascular Center, University of Colorado
More informationSevere Aortic Valve Disease: TAVR in Four Ages and Four Etiologies Age 25 y/o Congenital, 50 y/o Bicuspid, 75 y/o Rheumatic, 100 y/o Degenerative
Severe Aortic Valve Disease: TAVR in Four Ages and Four Etiologies Age 25 y/o Congenital, 50 y/o Bicuspid, 75 y/o Rheumatic, 100 y/o Degenerative Samin K. Sharma, MD, FACC, FSCAI Director Clinical & Interventional
More informationTranscatheter Valve Replacement: Current State in 2017
Transcatheter Valve Replacement: Current State in 2017 Marc A. Sintek MD Assistant Professor of Medicine Interventional Cardiology Cardiovascular Division Washington University in St. Louis Missouri ACP
More informationAortic Stenosis: Interventional Choice for a 70-year old- SAVR, TAVR or BAV? Interventional Choice for a 90-year old- SAVR, TAVR or BAV?
Aortic Stenosis: Interventional Choice for a 70-year old- SAVR, TAVR or BAV? Interventional Choice for a 90-year old- SAVR, TAVR or BAV? Samin K Sharma, MD, FACC, FSCAI Director Clinical & Interventional
More informationWatchman and Structural update..the next frontier. Ari Chanda, MD Cardiology Associates of Fredericksburg
Watchman and Structural update..the next frontier Ari Chanda, MD Cardiology Associates of Fredericksburg Different Left Atrial Appendage (LAA) morphologies Watchman (the device) Fabric Anchors Device structure
More informationManaging the Low Output Low Gradient Aortic Stenosis Patient
Managing the Low Output Low Gradient Aortic Stenosis Patient R A Nishimura MD Judd and Mary Leighton Professor of CV Mayo Clinic No disclosures Valvular Stenosis Severity of Aortic Stenosis Mean gradient
More informationAfter PARTNER 2A/S3i and SURTAVI: What is the Role of Surgery in Intermediate-Risk AS Patients?
After PARTNER 2A/S3i and SURTAVI: What is the Role of Surgery in Intermediate-Risk AS Patients? Vinod H. Thourani, MD Professor of Surgery and Medicine Emory University Disclosure Statement of Financial
More informationPercutaneous Therapy for Calcific Mitral Valve Disease
31 st Annual State of the Art Echocardiography San Diego, CA February 18, 2018 5:00 5:15 PM 15 min Percutaneous Therapy for Calcific Mitral Valve Disease Muhamed Sarić MD, PhD, MPA Director of Noninvasive
More informationThe FORMA Early Feasibility Study: 30-Day Outcomes of Transcatheter Tricuspid Valve Therapy in Patients with Severe Secondary Tricuspid Regurgitation
The FORMA Early Feasibility Study: 30-Day Outcomes of Transcatheter Tricuspid Valve Therapy in Patients with Severe Secondary Tricuspid Regurgitation Susheel Kodali, MD Director, Structural Heart & Valve
More informationCARDIOLOGY GRAND ROUNDS
CARDIOLOGY GRAND ROUNDS Presentation: Speakers: Percutaneous Repair of Paravalvular Prosthetic Regurgitation Paul Sorajja, MD Director of the Center for Valve and Structural Heart Disease Minneapolis Heart
More informationEmergency TAVI: Does It Exist? Is the Risk Higher?
Emergency TAVI: Does It Exist? Is the Risk Higher? Gerald Yong MBBS (Hons) FRACP FSCAI Interventional Cardiologist Royal Perth Hospital Western Australia APCASH 12 October 2014 Disclosure Statement of
More informationDiastolic Heart Function: Applying the New Guidelines Case Studies
Diastolic Heart Function: Applying the New Guidelines Case Studies Mitral Regurgitation The New ASE William Guidelines: A. Zoghbi Role MD, of FASE, 2D/3D MACCand CMR Professor and Chairman, Department
More informationObjectives. Considerations in management of multivalvular disease. Case Discussions. A Systematic Approach to Multivalve Disease.
A Systematic Approach to Multivalve Disease James D. Thomas, MD, FACC, FASE Director, Center for Heart Valve Disease Bluhm Cardiovascular Institute Professor of Medicine, Feinberg School of Medicine, Northwestern
More informationUpdate on Percutaneous Therapies for Structural Heart Disease. William Thomas MD Director of Structural Heart Program Tucson Medical Center
Update on Percutaneous Therapies for Structural Heart Disease William Thomas MD Director of Structural Heart Program Tucson Medical Center NCVH 2014- Tucson Disclosure of Financial Interest Research: Stock
More informationFive-Year Outcomes of Transcatheter Aortic Valve Replacement (TAVR) in Inoperable Patients With Severe Aortic Stenosis: The PARTNER Trial
Five-Year Outcomes of Transcatheter Aortic Valve Replacement (TAVR) in Inoperable Patients With Severe Aortic Stenosis: The PARTNER Trial Samir R. Kapadia, MD On behalf of The PARTNER Trial Investigators
More informationPutting together a structural heart program from the imagers perspective
Putting together a structural heart program from the imagers perspective Stephen H. Little, MD John S. Dunn Chair in Cardiovascular Research and Education, Associate professor, Weill Cornell Medicine Structural
More informationOptions for my no option Patients Treating Heart Conditions Via a Tiny Catheter
Options for my no option Patients Treating Heart Conditions Via a Tiny Catheter Nirat Beohar, MD Associate Professor of Medicine Director Cardiac Catheterization Laboratory, Medical Director Structural
More informationMITRAL STENOSIS: MANY FLAVORS Rheumatic and Calcification. Rheumatic Mitral Stenosis 76yo male
MITRAL STENOSIS: MANY FLAVORS Rheumatic and Calcification David S Rubenson MD FACC FASE Founding Director, Cardiac Non-Invasive Laboratory Scripps Clinic Medical Group number 1 Rheumatic Mitral Stenosis
More informationBioprosthetic Mitral Valve Dysfunction: Innovation and Evolution of a New Therapeutic Technique
Bioprosthetic Mitral Valve Dysfunction: Innovation and Evolution of a New Therapeutic Technique Charanjit S. Rihal MD MBA Professor and Chair Division of Cardiovascular Diseases Mayo Clinic DISCLOSURES
More informationDobutamine Stress testing In Low Flow, Low EF, Low Gradient Aortic Stenosis Case Studies
Dobutamine Stress testing In Low Flow, Low EF, Low Gradient Aortic Stenosis Case Studies Mitral Regurgitation The New ASE Guidelines: Role of 2D/3D and CMR William A. Zoghbi MD, FASE, MACC Professor and
More information7 th Conference of Transcatheter Heart Valve Therapies
7 th Conference of Transcatheter Heart Valve Therapies May 18-19, 2018, Athens Hilton Athens, Greece Course Directors Stratis Pattakos MD Konstantinos Spargias MD Panos Vardas MD Co-Directors Nick Bouboulis
More informationSuccessful Percutaneous Closure of Mitral Bioprosthetic Paravalvular Leak Using Figulla ASD Occluder
Hans R. Figulla, M.D., PhD ; Ali Hamadanchi, M.D. Medicine, Pneumology Universitity Hospital, Jena, Germany Successful Percutaneous Closure of Mitral Bioprosthetic Paravalvular Leak Using Figulla ASD Occluder
More information22/06/2017. Oxford City. Transcatheter aortic valve replacement 2017 guidelines. 1. First time I have heard about it. 2.
Oxford City Transcatheter aortic valve replacement 2017 guidelines Monday 19 th June Jim Newton Oxford Oxford University Hospitals NHS FT How familiar are you with TAVR? 1. First time I have heard about
More informationWhat to do with a Patient with Recurrent MR after Intervention
What to do with a Patient with Recurrent MR after Intervention James D. Thomas, MD, FACC, FASE Director, Center for Heart Valve Disease Bluhm Cardiovascular Institute Professor of Medicine, Feinberg School
More informationTAVI and TAVR: Radical and Revolutionary: The Newest Insights for the CV Community and a Panel Discussion
TAVI and TAVR: Radical and Revolutionary: The Newest Insights for the CV Community and a Panel Discussion Moderator: Joseph E. Bavaria, MD Roberts-Measey Professor of Surgery Vice Chair, Division of Cardiovascular
More informationAortic Stenosis Background and Breakthroughs in Treatment: TAVR Update
Aortic Stenosis Background and Breakthroughs in Treatment: TAVR Update Howard J Broder MD Interventional Cardiology DaVita Medical Group/ Healthcare Partners Cardiology Disclosures for Howard J Broder
More informationTAVR Cases. Disclosures 2/17/2018. February 17, :15 3:30 PM 15 min
31 st Annual State of the Art Echocardiography San Diego, CA February 17, 2018 3:15 3:30 PM 15 min TAVR Cases Muhamed Sarić MD, PhD, MPA Director of Noninvasive Cardiology Echo Lab Associate Professor
More informationStrokes After TAVR Reasons for Declining Frequency
Strokes After TAVR Reasons for Declining Frequency Samir Kapadia, MD Professor of Medicine Director, Cardiac Catheterization Laboratory Cleveland Clinic Disclosure NONE Second Generation Valves Newer
More information«Paradoxical» low-flow, low-gradient AS with preserved LV function: A Silent Killer
«Paradoxical» low-flow, low-gradient AS with preserved LV function: A Silent Killer Philippe Pibarot, DVM, PhD, FACC, FAHA, FESC, FASE Canada Research Chair in Valvular Heart Diseases Université LAVAL
More informationSAPIEN 3: Evaluation of a Balloon- Expandable Transcatheter Aortic Valve in High-Risk and Inoperable Patients With Aortic Stenosis One-Year Outcomes
SAPIEN 3: Evaluation of a Balloon- Expandable Transcatheter Aortic Valve in High-Risk and Inoperable Patients With Aortic Stenosis One-Year Outcomes Howard C. Herrmann, MD on behalf of The PARTNER II Trial
More informationValvular Heart Disease Transcatheter Valve Therapies. October 2016 Brian Whisenant MD
Valvular Heart Disease Transcatheter Valve Therapies October 2016 Brian Whisenant MD Disclosure Statement of Financial Interest Within the past 12 months, I or my spouse/partner have had a financial interest/arrangement
More informationIncorporating the intermediate risk in Transcatheter Aortic Valve Implantation (TAVI)
Incorporating the intermediate risk in Transcatheter Aortic Valve Implantation (TAVI) Larry S. Dean, MD, MSCAI Past President SCAI Professor of Medicine and Surgery University of Washington School of Medicine
More informationECHO HAWAII. Role of Stress Echo in Valvular Heart Disease. Not only ischemia! Cardiomyopathy. Prosthetic Valve. Diastolic Dysfunction
Role of Stress Echo in Valvular Heart Disease ECHO HAWAII January 15 19, 2018 Kenya Kusunose, MD, PhD, FASE Tokushima University Hospital Japan Not only ischemia! Cardiomyopathy Prosthetic Valve Diastolic
More informationLow Gradient Severe? AS
Low Gradient Severe? AS Philippe Pibarot, DVM, PhD, FACC, FAHA, FESC, FASE Canada Research Chair in Valvular Heart Diseases Institut Universitaire de Cardiologie et de Pneumologie de Québec / Québec Heart
More informationAortic stenosis with concomitant mitral regurgitation
Challenges in the evaluation and management of aortic stenosis Aortic stenosis with concomitant mitral regurgitation S1 Philippe Unger, M.D., FESC Erasme Hospital - Université Libre de Bruxelles Brussels,
More informationMarch yr. old male, newspaper writer, with worsening dyspnea /orthopnea past few months
Case 1 March 2016 59 yr. old male, newspaper writer, with worsening dyspnea /orthopnea past few months PMH diabetes, celiac disease Reports chest discomfort, positional coughing and pedal edema last 10
More informationPercutaneous Valve in Native With and Without Mitral Valve Calcification: When To Go Hybrid
Percutaneous Valve in Native With and Without Mitral Valve Calcification: When To Go Hybrid Deborah Tabachnick, MD Cardiac Surgeon The Heart Hospital Baylor Plano Baylor Scott & White Health Disclosures
More informationWelcome 17 Michigan TAVR Participating Hospitals!
Welcome 17 Michigan TAVR Participating Hospitals! 1 MICHIGAN TAVR BRIEF OVERVIEW HOW AND WHY PRE-TAVR IMAGING EVALUATION AND THE TVT Michael Grossman, MD Co-Director, BMC2 Coordinating Center Why Michigan
More informationTAVR IN INTERMEDIATE-RISK PATIENTS
TAVR IN INTERMEDIATE-RISK PATIENTS K. Lampropoulos MD, PhD, FESC, MEAPCI Interventional Cardiologist Evangelismos General Hospital The Burden of Valve Disease Prevalence Survival NATURAL HISTORY OF AS
More informationNew Therapies for the Heart Patient. Wilson They said "There's nothing more that can be done." Robert Federici MD, Presbyterian Heart
New Therapies for the Heart Patient Wilson 2016 They said "There's nothing more that can be done." Robert Federici MD, Presbyterian Heart Disclosure Boston Scientific Physician Proctor for CTO's, Clinical
More informationAn Overview of Mainstream Structural Heart Therapies: TAVR/MitraClip/Watchman
An Overview of Mainstream Structural Heart Therapies: TAVR/MitraClip/Watchman Yakima Valley Medical Conference Moses Mathur MD MSc March 2018 Outline CC : 85 yo M w/ Shortness of breath TTE : Cardiomyopathy
More informationTAVR: Echo Measurements Pre, Post And Intra Procedure
2017 ASE Florida, Orlando, FL October 10, 2017 8:00 8:25 AM 25 min TAVR: Echo Measurements Pre, Post And Intra Procedure Muhamed Sarić MD, PhD, MPA Director of Noninvasive Cardiology Echo Lab Associate
More informationTranscatheter Therapies For Aortic Valve Disease. March 2017 Brian Whisenant MD
Transcatheter Therapies For Aortic Valve Disease March 2017 Brian Whisenant MD Introduction I got into this field to protect my turf. I must say, I have come full circle... - Kent W. Jones I got into this
More information*Core lab for numerous trials, for which I receive no direct compensation from sponsors.
Rebecca T. Hahn, MD, FACC, FASE Director of Interventional Echo Professor of Medicine Columbia University Company Abbott Vascular Gore&Assoc NaviGATE Medtronic Boston Scientific GE Medical Philips Healthcare
More informationClinical Value of 3D Echo: Volumes and Valves
Clinical Value of 3D Echo: Volumes and Valves James D. Thomas, M.D., F.A.C.C. Cardiovascular Imaging Center Department of Cardiology Cleveland Clinic Foundation Cleveland, Ohio, USA Conflicts: None 3D2011:1
More informationAortic Stenosis: Open vs TAVR vs Nothing
Aortic Stenosis: Open vs TAVR vs Nothing Wilson Y. Szeto, MD Associate Professor of Surgery Surgical Director, Transcatheter Cardio-Aortic Therapies Associate Director, Thoracic Aortic Surgery Division
More informationPARAVALVULAR LEAK POST TAVR. Elements of Follow-up Post TAVR
PARAVALVULAR LEAK POST TAVR David S Rubenson MD FACC FASE Founding Director, Cardiac Non-Invasive Laboratory Scripps Clinic Medical Group number 1 Elements of Follow-up Post TAVR JACC CV Imag 2016;9:193
More informationTREATMENT OF MITRAL REGURGITATION RAJA NAZIR FACC
TREATMENT OF MITRAL REGURGITATION RAJA NAZIR FACC NATURAL HISTORY OF MITRAL REGURGITATION Abdallah El Sabbagh et al. JIMG 2018;11:628-643 TREATMENT OPTIONS SURGERY REPAIR REPLACEMENT PERCUTANEOUS INTERVENTIONS
More informationCatheter Based Valve Interventions. Matthew Caldwell, MD February 5, 2019 Puerto Vallarta, Mexico
Catheter Based Valve Interventions Matthew Caldwell, MD February 5, 2019 Puerto Vallarta, Mexico Relevance to Non-Cardiac Anesthesiologist Approx 12% of adults >75 years have mod-severe valve disease
More informationTRANSCATHETER AORTIC VALVE IMPLANTATION: PSCC EXPERIENCE DR HUSSEIN ALAMRI PSCC RIYADH
TRANSCATHETER AORTIC VALVE IMPLANTATION: PSCC EXPERIENCE DR HUSSEIN ALAMRI PSCC RIYADH Available systems: Edwards (TA and TF) and Core valve. INTRODUCTION 3 4% 0f > 65 y. 30 40% of elderly denied surgery,.
More informationTranscatheter Valve Therapies Update
Providence Heart and Vascular Institute Transcatheter Valve Therapies Update Where In The H*@# Is All This Going??? Robert Hodson MD Medical Director, Providence Valve Center October 24, 2015 DISCLOSURES
More information2/28/2010. Speakers s name: Paul Chiam. I have the following potential conflicts of interest to report: NONE. Antegrade transvenous transseptal route
Transcatheter Aortic Valve Implantation Asian perspective Speakers s name: Paul Chiam Paul TL Chiam MBBS, MRCP, FACC I have the following potential conflicts of interest to report: NONE Consultant National
More informationAortic Valvular Stenosis
Aortic Valvular Stenosis How to Assess the Four Variables for Management Low Flow / Low Gradient / Normal EF / Low EF Patrick T. O Gara, MD, MACC Brigham and Women s Hospital Harvard Medical School No
More informationIndication, Timing, Assessment and Update on TAVI
Indication, Timing, Assessment and Update on TAVI Swedish Heart and Vascular Institute Ming Zhang MD PhD Interventional Cardiology Structure Heart Disease Conflict of Interest None Starr- Edwards Mechanical
More informationMinimalist Transcatheter Aortic Valve Replacement (MA-TAVR)
Minimalist Transcatheter Aortic Valve Replacement (MA-TAVR) Jensen HA, Condado JF, Devireddy C, Binongo JN, Leshnower BG, Babaliaros V, Sarin EL, Lerakis S, Guyton RA, Stewart JP, Syed AQ, Mavromatis K,
More informationTAVR for Complex Aortic Valvular Conditions
TAVR for Complex Aortic Valvular Conditions Wilson Y. Szeto, MD Professor of Surgery Chief, Cardiovascular Surgery at Penn Presbyterian Surgical Director, Transcatheter Cardio-Aortic Therapies Associate
More informationStress Echocardiography: Illustrative Cases Sunil Mankad, MD, FACC, FCCP, FASE Associate Professor of Medicine Mayo Clinic College of Medicine Director, Transesophageal Echocardiography Associate Director,
More informationMITRAL (Mitral Implantation of TRAnscatheter valves)
MITRAL (Mitral Implantation of TRAnscatheter valves) 30-Day Outcomes of Transcatheter MV Replacement in Patients With Severe Mitral Valve Disease Secondary to Mitral Annular Calcification or Failed Annuloplasty
More informationPrince Sultan Cardiac Center Experience Riyadh, Saudi Arabia
Transcatheter Transapical Aortic Valve Implantation Prince Sultan Cardiac Center Experience Riyadh, Saudi Arabia Ahmed Elwatidy, MD,PhD, FRCS S Kassab, MD,S Ahmari, MD, H Amri, MD, H Ismail, MD, A Calafiori,
More informationAortic Valve Stenosis and TAVR: Putting it all together.
Aortic Valve Stenosis and TAVR: Putting it all together. Maria L. Held, MSN CNS Valve Clinic Coordinator at The Cleveland Clinic Alliance of Cardiovascular Professionals April 14 th, 2018 Brief Anatomy
More informationStructural Heart Disease Conference: Aortic Valve and Beyond. Fifth Annual. May 19, 2017 THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER
THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER Fifth Annual Structural Heart Disease Conference: Aortic Valve and Beyond May 19, 2017 Ohio State University The Ohio Union 1739 N. High Street, Columbus,
More informationPotential conflicts of interest
Potential conflicts of interest Speaker's name: Petros Dardas MEDTRONIC proctor for TAVI Intermediate risk 83 FEMALE COAD SEVERE AS NYHA III Mean gradient 35 mmhg, AVA 0.45cm2, SVI 21ml/m2 Paradoxical
More informationIs TAVR Now Indicated in Even Low Risk Aortic Valve Disease Patients
Is TAVR Now Indicated in Even Low Risk Aortic Valve Disease Patients Saibal Kar, MD, FACC, FAHA, FSCAI Director of Interventional Cardiac Research Cedars Sinai Heart Institute, Los Angeles, CA Potential
More informationValve Disease. Valve Surgery. Total Volume. In 2016, Cleveland Clinic surgeons performed 3039 valve surgeries.
Valve Surgery Total Volume 1 1 Volume 35 3 5 15 1 5 1 13 1 N = 773 5 79 15 93 1 339 In 1, surgeons performed 339 valve surgeries. surgeons have implanted more than 1, bioprosthetic aortic valves since
More informationDISCLOSURE. Relevant Financial Relationship(s) Off Label Usage. None. None
Echo for TAVR Sunil Mankad, MD, FACC, FCCP, FASE Associate Professor of Medicine Mayo Clinic College of Medicine Director, Transesophageal Echocardiography Associate Director, Cardiology Fellowship Mayo
More informationAssessment and Preparation of Patients with TAVI. Rob Tanzola Associate Professor, Queen s University
Assessment and Preparation of Patients with TAVI Rob Tanzola Associate Professor, Queen s University My patient has aortic stenosis and needs non-cardiac surgery Should (s)he get a TAVI? Rob Tanzola Associate
More informationGet Ready for Percutaneous Mitral Valve Approaches
Get Ready for Percutaneous Mitral Valve Approaches Paul A. Grayburn, MD Baylor Scott and White Healthcare System The Heart Hospital Baylor Plano and Baylor Heart and Vascular Hospital Dallas, TX HOPE Unmet
More informationWorldwide rheumatic fever is the most common cause of valve disease. In industrialized areas, valvular disease of old age predominates
Michael Sumners DO Epidemiology Worldwide rheumatic fever is the most common cause of valve disease In industrialized areas, valvular disease of old age predominates Calcific aortic stenosis Functional
More informationStress Testing in Valvular Disease
2017 ASE Florida Orlando, FL October 10, 2017 2:40 2:50 PM 10 min Grand Harbor Ballroom South Stress Testing in Valvular Disease Muhamed Sarić MD, PhD, MPA Director of Noninvasive Cardiology Echo Lab Associate
More informationTAVI After PARTNER-2 : The Hamilton Approach
TAVI After PARTNER-2 : The Hamilton Approach James L. Velianou MD FRCPC Interventional Cardiology Hamilton General Hospital St Catharines General Hospital Associate Professor of Medicine McMaster University
More informationThe Mitral Revolution: Transcatheter Repair (and Replacement?) Going Mainstream
The Mitral Revolution: Transcatheter Repair (and Replacement?) Going Mainstream Matthew J. Price MD Director, Cardiac Catheterization Laboratory Scripps Clinic La Jolla, CA, USA price.matthew@scrippshealth.org
More informationValvular Intervention
Valvular Intervention Outline Introduction Aortic Stenosis Mitral Regurgitation Conclusion Calcific Aortic Stenosis Deformed Eccentric Calcified Nodular Rigid HOSTILE TARGET difficult to displace prone
More informationEchocardiographic Evaluation of Aortic Valve Prosthesis
Echocardiographic Evaluation of Aortic Valve Prosthesis Amr E Abbas, MD, FACC, FASE, FSCAI, FSVM, RPVI Co-Director, Echocardiography, Director, Interventional Cardiology Research, Beaumont Health System
More informationPercutaneous Mitral Valve Repair
Percutaneous Mitral Valve Repair MitraClip: Procedure, Data, Patient Selection Chad Rammohan, MD FACC Director, Cardiac Cath Lab El Camino Hospital Mountain View, California Mitral Regurgitation MitraClip
More informationPrimary Mitral Valve Disease: Natural History & Triggers for Intervention ACC Latin American Conference 2017
Disclosures: GE stock, Primary Mitral Valve Disease: Natural History & Triggers for Intervention ACC Latin American Conference 2017 Athena Poppas, MD FACC Past ACC Scientific Sessions Chair, ACC Board
More informationSeverity of AS Degree of AV calcification (? Bicuspid AV), annulus size, & aortic root
The role of Cardiac Imaging modalities in evaluation & selection of patients for Trans-catheter Aortic Valve Implantation Dr.Saeed AL Ahmari Consultant Cardiologist Prince Sultan Cardaic Center, Riyadh
More informationChallenging Case. 89 year old man 5/11/2016. Prior 31 mm CoreValve NYHA III Moderately-severe PVL
5/11/2016 Vumedi May 2016 89 year old man Challenging Case Prior 31 mm CoreValve NYHA III Moderately-severe PVL Paul Sorajja, MD Director, Center for Valve and Structural Heart Disease Minneapolis Heart
More informationIan T. Meredith AM. MBBS, PhD, FRACP, FCSANZ, FACC, FAPSIC. Monash HEART, Monash Health & Monash University Melbourne, Australia
Two-Year Outcomes With the Fully Repositionable and Retrievable Lotus Transcatheter Aortic Replacement Valve in 120 High-Risk Surgical Patients With Severe Aortic Stenosis: Results From the REPRISE II
More informationTHE PERCUTANEOUS MANAGEMENT OF VALVULAR HEART DISEASE DR JOHN RAWLINS CONSULTANT INTERVENTIONAL CARDIOLOGIST UNIVERSITY HOSPITAL SOUTHAMPTON
THE PERCUTANEOUS MANAGEMENT OF VALVULAR HEART DISEASE DR JOHN RAWLINS CONSULTANT INTERVENTIONAL CARDIOLOGIST UNIVERSITY HOSPITAL SOUTHAMPTON INTRODUCTION History of heart valve intervention Current indications
More informationComplicated Percutaneous Repair of a Paravalvular Mitral Leak. Dr. K Kam Resident Specialist Division of Cardiology, PWH M&T (Courtesy: Prof.
Complicated Percutaneous Repair of a Paravalvular Mitral Leak Dr. K Kam Resident Specialist Division of Cardiology, PWH M&T (Courtesy: Prof. PW Lee) A new job for echo guy Interventional echocardiologist!
More informationTAVR today: High Risk, Intermediate Risk Population, and Valve in Valve Therapy
TAVR today: High Risk, Intermediate Risk Population, and Valve in Valve Therapy Alan Zajarias, MD FACC Structural Interventional Fellowship Director Associate Professor Medicine Cardiovascular Division
More informationHow does taking warfarin affect Exercise Regimen? By Dr.*~LoOKTaO ~* ÿ
How does taking warfarin affect Exercise Regimen? By Dr.*~LoOKTaO ~* ÿ no consistent recommendations available regarding safety of certain sports & exercise any sports w/ high risk of trauma, especially
More informationEchocardiographic Evaluation of Aortic Valve Prosthesis
Echocardiographic Evaluation of Aortic Valve Prosthesis Amr E Abbas, MD, FACC, FASE, FSCAI, FSVM, RPVI Co Director, Echocardiography, Director, Interventional Cardiology Research, Beaumont Health System
More informationA Surgeon s Perspective Guidelines for the Management of Patients with Valvular Heart Disease Adapted from the 2006 ACC/AHA Guideline Revision
A Surgeon s Perspective Guidelines for the Management of Patients with Valvular Heart Disease Adapted from the 2006 ACC/AHA Guideline Revision Prof. Pino Fundarò, MD Niguarda Hospital Milan, Italy Introduction
More informationUpdate on Transcatheter Mitral Valve Repair and Replacment
Update on Transcatheter Mitral Valve Repair and Replacment Vinod H. Thourani, MD Professor of Surgery Chair, Department of Cardiac Surgery Medstar Heart and Vascular Washington Hospital Center Georgetown
More informationCase Presentations TAVR: The Good Bad and The Ugly
Case Presentations TAVR: The Good Bad and The Ugly Vincent J. Pompili, MD, FACC, FSCAI Professor of Internal Medicine Director of Interventional Cardiovascular Medicine and Cardiac Catheterization Laboratories
More informationSONOGRAPHER & NURSE LED VALVE CLINICS
SONOGRAPHER & NURSE LED VALVE CLINICS Frequency of visits and alerts AORTIC STENOSIS V max > 4.0 m/s or EOA < 1.0 cm 2 V max 3.5 4.0 m/s + Ca+ V max 3.0 4.0 m/s or EOA 1.0-1.5 cm 2 V max 2.5 3.0 m/s every
More informationTAVR SPRING 2017 The evolution of TAVR
TAVR SPRING 2017 The evolution of TAVR Matthew Johnson, MD Disclosers None Evolution of the Balloon- Expandable Transcatheter Valves Cribier 2002 SAPIEN 2006 SAPIEN XT 2009 SAPIEN 3 2013 * Sheath compatibility
More informationPrognostic Impact of FMR
Secondary Mitral Valve Regurgitation in Heart Failure, Age 60 Years From Medical Therapy to Surgical Repair to Transcatheter Intervention The Interventionalist s View Samin K Sharma, MD, FACC, FSCAI Director
More informationStructural Heart Disease: Setting the Stage for Success
Structural Heart Disease: Setting the Stage for Success Brenda McCulloch, RN MSN RCIS Cardiovascular Clinical Nurse Specialist, Interventional & Medical Cardiology Sutter Medical Center, Sacramento mccullb@sutterhealth.org
More informationPercutaneous aortic valve replacement should NOT be preferred therapy for aortic stenosis
Percutaneous aortic valve replacement should NOT be preferred therapy for aortic stenosis James Bartholomew McClurken, MD FACC, FCCP, FACS, FESC Professor & Vice-Chair of Surgery, Temple University Hosp.,
More information3D Printing & Echocardiography
Echo Hawaii Jan 18, 2018 3D Printing & Echocardiography Stephen H. Little, MD John S. Dunn Chair in Cardiovascular Research and Education, Associate professor, Weill Cornell Medicine Rapid Prototyping
More information